Diabetes drug metformin shows promise in slowing CLL progression
NCT ID NCT01750567
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tested whether metformin, a common diabetes drug, could help control chronic lymphocytic leukemia (CLL) in 37 patients whose cancer had returned or who had a high-risk genetic type. Metformin is cheap and generally safe, and it may slow cancer growth by lowering insulin levels and blocking certain cell signals. The goal was to see if metformin could delay the need for stronger treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.